Chemotherapy and immunotherapy: Mapping the road ahead

Alistair M. Cook; Willem J. Lesterhuis; Anna K. Nowak; Richard A. Lake

doi:10.1016/j.coi.2015.12.003

Chemotherapy and immunotherapy: Mapping the road ahead

Alistair M. Cook, Willem J. Lesterhuis, Anna K. Nowak, Richard A. Lake

Research output: Contribution to journal › Review article

89 Citations (Scopus)

Abstract

© 2015 Elsevier Ltd. Cancer immunotherapy, and in particular checkpoint blockade, is now standard clinical care for a growing number of cancers. Cytotoxic drugs have been the primary weapon against cancer for a long time and have typically been understood because of their capacity to directly kill tumour cells. It is now clear that these drugs are potential partners for checkpoint blockade and different drugs can influence the immune response to cancer through a wide variety of mechanisms. Some of these relate to immunogenic cell death, whilst others relate to changes in antigen-presentation, tumour cell targeting, or depletion of immunosuppressive cells. Here, we review some recent advances in our understanding of the immunological changes associated with chemotherapy, discuss progress in combining chemotherapy with checkpoint blockade, and comment on the difficulties encountered in translating promising preclinical data into successful treatments for cancer patients.

Original language	English
Pages (from-to)	23-29
Number of pages	7
Journal	Current Opinion in Immunology
Volume	39
DOIs	https://doi.org/10.1016/j.coi.2015.12.003
Publication status	Published - 1 Apr 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.coi.2015.12.003

Cite this

@article{2ec5f2762d4f4f79bca3154580357be0,

title = "Chemotherapy and immunotherapy: Mapping the road ahead",

abstract = "{\textcopyright} 2015 Elsevier Ltd. Cancer immunotherapy, and in particular checkpoint blockade, is now standard clinical care for a growing number of cancers. Cytotoxic drugs have been the primary weapon against cancer for a long time and have typically been understood because of their capacity to directly kill tumour cells. It is now clear that these drugs are potential partners for checkpoint blockade and different drugs can influence the immune response to cancer through a wide variety of mechanisms. Some of these relate to immunogenic cell death, whilst others relate to changes in antigen-presentation, tumour cell targeting, or depletion of immunosuppressive cells. Here, we review some recent advances in our understanding of the immunological changes associated with chemotherapy, discuss progress in combining chemotherapy with checkpoint blockade, and comment on the difficulties encountered in translating promising preclinical data into successful treatments for cancer patients.",

author = "Cook, {Alistair M.} and Lesterhuis, {Willem J.} and Nowak, {Anna K.} and Lake, {Richard A.}",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.coi.2015.12.003",

language = "English",

volume = "39",

pages = "23--29",

journal = "Current Opinion in Immunology",

issn = "0952-7915",

publisher = "Elsevier",

}

TY - JOUR

T1 - Chemotherapy and immunotherapy: Mapping the road ahead

AU - Cook, Alistair M.

AU - Lesterhuis, Willem J.

AU - Nowak, Anna K.

AU - Lake, Richard A.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - © 2015 Elsevier Ltd. Cancer immunotherapy, and in particular checkpoint blockade, is now standard clinical care for a growing number of cancers. Cytotoxic drugs have been the primary weapon against cancer for a long time and have typically been understood because of their capacity to directly kill tumour cells. It is now clear that these drugs are potential partners for checkpoint blockade and different drugs can influence the immune response to cancer through a wide variety of mechanisms. Some of these relate to immunogenic cell death, whilst others relate to changes in antigen-presentation, tumour cell targeting, or depletion of immunosuppressive cells. Here, we review some recent advances in our understanding of the immunological changes associated with chemotherapy, discuss progress in combining chemotherapy with checkpoint blockade, and comment on the difficulties encountered in translating promising preclinical data into successful treatments for cancer patients.

AB - © 2015 Elsevier Ltd. Cancer immunotherapy, and in particular checkpoint blockade, is now standard clinical care for a growing number of cancers. Cytotoxic drugs have been the primary weapon against cancer for a long time and have typically been understood because of their capacity to directly kill tumour cells. It is now clear that these drugs are potential partners for checkpoint blockade and different drugs can influence the immune response to cancer through a wide variety of mechanisms. Some of these relate to immunogenic cell death, whilst others relate to changes in antigen-presentation, tumour cell targeting, or depletion of immunosuppressive cells. Here, we review some recent advances in our understanding of the immunological changes associated with chemotherapy, discuss progress in combining chemotherapy with checkpoint blockade, and comment on the difficulties encountered in translating promising preclinical data into successful treatments for cancer patients.

U2 - 10.1016/j.coi.2015.12.003

DO - 10.1016/j.coi.2015.12.003

M3 - Review article

C2 - 26724433

VL - 39

SP - 23

EP - 29

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

ER -

Chemotherapy and immunotherapy: Mapping the road ahead

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this